SPDR S&P Biotech ETF
XBI · etf · 3 prediction records
Publication markers · exact horizontal time
Prediction 1 Prediction published1 Headline publishedPrediction 1 entry priceGraph badges open evidence. Timeline items jump to matching cards.
Chart readoutPrediction 1 is Rise expected ↑. Visible result record: No result recorded. 3 of 3 timed publication events are placed from left to right.
Latest public price · never a ledger grade- Last public price
- Loading public price data…
- From Prediction 1 entry
- Entry 157.41 USD
- Latest call
- Rise expected ↑
- Publication markers
- 3 of 3 timed
Publication timelineOldest → newest
Left to right matches the graph. Select an event to jump to its full card.
- Prediction 3Prediction Prediction 3 · 11 Aug 2026, 10:17 SGTRise expected prediction158.03 USD · No result recorded
- Prediction 2Prediction Prediction 2 · 14 Aug 2026, 09:32 SGTRise expected prediction156.86 USD · PROOF RECEIPT · Right (NOT FOUNDER-STAMPED)
- Prediction 1Prediction Prediction 1 · 15 Aug 2026, 12:19 SGTRise expected prediction157.41 USD · No result recorded
Latest prediction · Prediction 1
-
Prediction 1
Rise expected · 157.41 USDNo result recorded - Published
- Deadline
Headlines · 0 · oldest first
- No eligible linked headline exists in retained publication evidence for this investment. OTR does not invent an asset match or chart time, so there is no numbered headline marker yet.
Prediction history · 2 earlier · newest first
-
Prediction 2
Rise expected · 156.86 USDPROOF RECEIPT · Right (NOT FOUNDER-STAMPED) - Published
- Deadline
-
Prediction 3
Rise expected · 158.03 USDNo result recorded - Published
- Deadline
Graph LearningHow news has moved SPDR S&P Biotech ETF beforeOpen the complete asset-specific memory
OTR GRAPH LEARNING
An extra check. It does not replace the other evidence.What OTR sees for SPDR S&P Biotech ETF
What this is: An ETF tracking an equal-weighted-style basket of U.S. biotechnology companies, including many smaller firms whose value depends heavily on clinical, regulatory, and financing milestones.
Headlines that may cause the price of this investment to go up
- FDA approvals, positive pivotal-trial results, or clinical holds lifted for meaningful portfolio holdings.
- Acquisitions, licensing deals, or partnerships with credible economics and upfront funding.
- Successful financing that extends cash runway without severe dilution.
Headlines that may cause the price of this investment to go down
- Failed trials, safety signals, FDA complete-response letters, or new clinical holds.
- Dilutive equity offerings, short cash runway, restructuring, or programme discontinuation.
- Drug-pricing, reimbursement, or regulatory changes that reduce expected commercial value.
What OTR checks
- XBI daily holdings and equal-weight rebalance dates
- FDA approval calendar, complete-response letters, and clinical holds
- Clinical-trial registry status and company-reported primary endpoints
- Cash, quarterly burn, debt, shelf registrations, and expected runway
0 saved news time checks0 completed0 rose0 fell0 roughly flat
No asset-specific news signal is stored yet.
No linked headline sentiment memory is available for this investment yet. OTR shows the gap instead of guessing.
Open the full Graph Learning analysis
- Past
- OTR has no source-timed headline response row for this investment yet. That missing history is shown, not guessed.
- Now
- News that may help includes FDA approvals, positive pivotal-trial results, or clinical holds lifted for meaningful portfolio holdings.; Acquisitions, licensing deals, or partnerships with credible economics and upfront funding.. News that may hurt includes Failed trials, safety signals, FDA complete-response letters, or new clinical holds.; Dilutive equity offerings, short cash runway, restructuring, or programme discontinuation.. OTR also watches XBI daily holdings and equal-weight rebalance dates, FDA approval calendar, complete-response letters, and clinical holds, Clinical-trial registry status and company-reported primary endpoints.
- Next prediction
- For a future prediction, OTR compares the new event with this investment's own saved reactions, then checks the wider market and named other possible causes. One headline never decides a call by itself.
- When this can mislead
- A dramatic result may affect one small holding but barely move the ETF.; Equal-weight rebalancing can change exposure around an event.; Headline endpoints can differ from prespecified primary endpoints and safety context.; An approval can be priced in or offset by a restrictive label and weak commercial economics.
Saved headline-move memory
No source-timed headline response is available yet. OTR shows the gap instead of guessing.
Clue, not proof: timing is a clue, never proof. A price move after a headline does not prove the headline caused it. OTR uses a pattern only after it repeats and still holds up against the wider market.